**Daunorubicin**

**Section:** 8. Immunomodulators and antineoplastics 〉 8.2. Antineoplastics and supportive medicines 〉 8.2.1. Cytotoxic medicines

---

**Indication**

Lymphoid leukaemia, not elsewhere classified  

**INN**

Daunorubicin

**Medicine type**

Chemical agent

**List type**

Complementary

**Formulations**

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

**EML status history**

First added in 1999 (TRS 895)  
Changed in 2002 (TRS 914)  
Changed in 2007 (TRS 950)  
Changed in 2015 (TRS 994)  
Changed in 2023 (TRS 1049)

**Sex**

All

**Age**

Also recommended for children

**Therapeutic alternatives**

The recommendation is for this specific medicine

**Patent information**

Patents have expired in most jurisdictions  
Read more about patents.

---

**Tags**

Cancer

**Wikipedia**

Daunorubicin

**DrugBank**

Daunorubicin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.